|Isis Pharmaceuticals, Inc.|
2855 Gazelle Court
United States - Map
Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The companys flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
|Isis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Stanley T. Crooke M.D., Ph.D.,
Founder, Exec. Chairman, Chief Exec. Officer, Pres, Chairman of Science/Medical Committee and Member of Agenda Committee
|Ms. Elizabeth L. Hougen ,
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
|Ms. B. Lynne Parshall Esq., J.D.,
Chief Operating Officer, Corp. Sec., Director and Member of Agenda Committee
|Dr. C. Frank Bennett BSc, Ph.D.,
Sr. VP of Antisense Research
|Dr. Richard S. Geary Ph.D.,
Sr. VP of Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|